anti-4CB1
Cancer (via HVEM blockade)
Pre-clinicalActive
Key Facts
About 4c Biomed
4C Biomed is a private, preclinical-stage biotech company developing novel cancer immunotherapies through its proprietary discovery platform. The company's core technology utilizes autologous patient-derived tumor and immune cell systems to functionally identify and validate new drug targets with high clinical relevance. Its most advanced asset, anti-4CB1, is a fully human monoclonal antibody designed to block the HVEM-BTLA/CD160 inhibitory axis and is progressing towards a planned Phase I trial in 2026. The company operates as a platform and therapeutics developer, seeking partnerships to leverage its target discovery capabilities.
View full company profile